ImmunityBio (IBRX) Change in Accured Expenses (2014 - 2026)

ImmunityBio (IBRX) has 13 years of Change in Accured Expenses data on file, last reported at $3.1 million in Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at $3.1 million, up 124.26% year-over-year; the trailing twelve-month figure through Mar 2026 was $19.3 million (up 448.55% YoY), and the FY2025 annual result was $3.2 million, up 311.14% from the prior year.
• Change in Accured Expenses rose to $3.1 million in Q1 2026 per IBRX's latest filing, from $1.9 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $18.6 million in Q1 2023 and troughed at -$19.5 million in Q4 2023.
• A 5-year average of $917882.4 and a median of $3.1 million in 2026 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2022 and 2023: Change in Accured Expenses jumped 675.33% in 2022, then plunged 519.36% in 2023.
• A 5-year view of Change in Accured Expenses shows it stood at -$3.2 million in 2022, then sank by 519.36% to -$19.5 million in 2023, then jumped by 89.17% to -$2.1 million in 2024, then soared by 191.06% to $1.9 million in 2025, then soared by 62.96% to $3.1 million in 2026.
• Business Quant data shows IBRX's Change in Accured Expenses at $3.1 million in Q1 2026, $1.9 million in Q4 2025, and $5.5 million in Q3 2025.